Skip to Main content Skip to Navigation
Master Thesis

Identification d’une signature métabolique prédictive de réponse aux inhibiteurs des points de contrôle immunitaires chez les patients atteints d’un cancer bronchique non à petites cellules : protocole et analyse intermédiaire

Abstract : Immune Checkpoint lnhibitors (ICI) are becoming new standards of care in Oncology, especially for the non-small cell lung cancer (NSCLC). Actually, no biomarker is sensitive and specific enough to predict their effectiveness. As the composition of the microbiota can influence the response to these treatments, we hypothesized that the metabolome, reflecting the function of the microbiota, could represent an effective biomarker. METABO-IPCI is a monocentric and prospective at University Hospital Grenoble Alpes whose main objective is to identify a metabolic signature predictive of response to ICI in patients with NSCLC. Secondary objectives are re to show an association between metabolome, microbiota composition, immunological profile and clinical response to ICI. The protocol includes 60 patients followed for NSCLC and treated with ICI as first line alone (Cohort 1 ), as second line or more (Cohort 2) or as first line in combination with chemotherapy (Cohort 3). At the 30th June 2021, 30 patients were included: 1 in Cohort 1, 19 in Cohort 2 and 10 in Cohort 3. The median age was 68 years old, 80% were adenocarcinoma. As part of the study, 94% of blood samples were collected, 72% of stool samples. At 2 months after the start of treatment, 9 patients (30%) had progressive disease, 15 (50%) stable disease and 6 (20%) had partial response disease. Given the delay in inclusions, the inclusion period has been extended to June 2022. Ali biological analyses will ail be performed 6 months after the last inclusion (starting in the first half of 2023).
Document type :
Master Thesis
Complete list of metadata

https://dumas.ccsd.cnrs.fr/dumas-03359294
Contributor : Jean-Hugues Morneau Connect in order to contact the contributor
Submitted on : Thursday, September 30, 2021 - 9:52:10 AM
Last modification on : Sunday, October 3, 2021 - 3:21:18 AM

File

2021GRAL5113_sannicolo_sara_di...
Files produced by the author(s)

Identifiers

  • HAL Id : dumas-03359294, version 1

Citation

Sarah Sannicolo. Identification d’une signature métabolique prédictive de réponse aux inhibiteurs des points de contrôle immunitaires chez les patients atteints d’un cancer bronchique non à petites cellules : protocole et analyse intermédiaire. Médecine humaine et pathologie. 2021. ⟨dumas-03359294⟩

Share

Metrics

Record views

21

Files downloads

4